Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis
- PMID: 31919705
- DOI: 10.1007/s10554-019-01681-y
Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis
Abstract
Although drug-coated balloon (DCB) angioplasty is an effective therapy for drug-eluting stent- in stent restenosis (DES-ISR) after coronary stenting, recurrent ISR after DCB angioplasty still occurs. Different patterns of DES-ISR responding to DCB are largely unknown. This study sought to assess outcomes of different patterns of DES-ISR treated with DCB. From December 2014 to December 2016, a total of 160 DES-ISR lesions treated with DCB were retrospectively evaluated. Restenosis patterns were classified into two groups according to Mehran classification: focal, defined as < 10 mm, 58 lesions (36.3%); non-focal, which were diffuse, proliferative, or obstructive, 102 lesions (63.7%). The primary endpoint was binary restenosis rate at 9-month angiographic follow-up. Secondary endpoint was major adverse cardiac events (MACE) at 24-month follow-up. Baseline characteristics were comparable between the two groups. Angiographic follow-up rate was 93.7% (93.1% in the focal group and 94.1% in the non-focal group). The focal group had a lower recurrent restenosis rate compared to the non-focal group (3.7% vs. 33.3%, respectively; P = 0.003) at an average angiographic follow-up of 10 (10.4 ± 6.2) months. There was no difference in MACE between the two groups (6.9% vs. 11.8%, respectively; P = 0.70) at (22.7 ± 9.1) months clinical follow-up. On multivariate logistic regression analysis, focal pattern (OR 13.033; 95% CI 2.441-69.573, P = 0.003) and post-procedure DS% (OR 1.142; 95% CI 1.070-1.218, P = 0.000) were predictive factors of binary restenosis after DCB angioplasty. On multivariate analysis, focal pattern of ISR was a predictive factor of MACE (OR 0.260; 95% CI 0.071-0.959, P = 0.043), and diabetes mellitus (DM) was an independent predictor of MACE after DCB angioplasty (OR 5.045; 95% CI 1.179-21.590, P = 0.029). The present study suggests that DCB provides much better clinical, angiographic outcomes in patients with focal DES-ISR than non-focal DES-ISR.
Keywords: Drug-coated balloon; Drug-eluting stent; In-stent restenosis; Recurrent in-stent restenosis.
Similar articles
-
Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.Heart Vessels. 2016 Sep;31(9):1405-11. doi: 10.1007/s00380-015-0741-6. Epub 2015 Sep 4. Heart Vessels. 2016. PMID: 26337620
-
Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.JACC Cardiovasc Interv. 2017 Jul 10;10(13):1332-1340. doi: 10.1016/j.jcin.2017.04.024. JACC Cardiovasc Interv. 2017. PMID: 28683939 Clinical Trial.
-
Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis.Int J Cardiol. 2024 Nov 15;415:132450. doi: 10.1016/j.ijcard.2024.132450. Epub 2024 Aug 13. Int J Cardiol. 2024. PMID: 39147282
-
Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.Catheter Cardiovasc Interv. 2018 Aug 1;92(2):285-299. doi: 10.1002/ccd.27359. Epub 2017 Oct 10. Catheter Cardiovasc Interv. 2018. PMID: 29024274
-
Long-term clinical safety and efficacy of drug-coated balloon in the treatment of in-stent restenosis: A meta-analysis and systematic review.Catheter Cardiovasc Interv. 2020 Aug;96(2):E129-E141. doi: 10.1002/ccd.28572. Epub 2019 Nov 12. Catheter Cardiovasc Interv. 2020. PMID: 31714010
Cited by
-
Clinical Outcomes of Drug-Coated Balloon in Coronary Patients with and without Diabetes Mellitus: A Multicenter, Propensity Score Study.J Diabetes Res. 2021 Jul 29;2021:5495219. doi: 10.1155/2021/5495219. eCollection 2021. J Diabetes Res. 2021. PMID: 34368364 Free PMC article.
-
Clinical outcomes of drug-coated balloon in coronary lesions: a real-world, all-comers study.Clin Res Cardiol. 2022 Jul;111(7):732-741. doi: 10.1007/s00392-021-01895-y. Epub 2021 Jul 27. Clin Res Cardiol. 2022. PMID: 34313800
-
Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease.J Interv Cardiol. 2021 Dec 1;2021:2632343. doi: 10.1155/2021/2632343. eCollection 2021. J Interv Cardiol. 2021. PMID: 34934407 Free PMC article.
-
Percutaneous Mechanical Atherectomy Plus Thrombectomy Using the Rotarex®S Device Followed by a Drug-Coated Balloon for the Treatment of Femoropopliteal Artery In-stent Restenosis: A Prospective Single-Center, Single-Arm Efficacy Trial (PERMIT-ISR Trial).Front Surg. 2021 Sep 14;8:671849. doi: 10.3389/fsurg.2021.671849. eCollection 2021. Front Surg. 2021. PMID: 34595204 Free PMC article.
-
Long-term outcomes of drug-coated balloon treatment of calcified coronary artery lesions: a multicenter, retrospective, propensity matching study.Front Cardiovasc Med. 2023 Jun 14;10:1122290. doi: 10.3389/fcvm.2023.1122290. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37388642 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources